HRS-1893 vs Mavacamten

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertrophic Cardiomyopathy

Shared mechanism: Cardiac myosin (inhibitor) · full Hypertrophic Cardiomyopathy pipeline

HRS-1893

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Hypertrophic Cardiomyopathyundisclosed
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07021963 (registry estimate)

No aligned efficacy figure on record for this race.

Mavacamten · Camzyos

Marketed by Bristol-Myers Squibb

Approved in Hypertrophic Cardiomyopathysmall molecule
Partial signal

NCT03470545 · Phase 3 · completed

EXPLORER-HCM was a randomized, double-blind, placebo-controlled Phase 3 trial in 251 adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint was a composite clinical response built from peak oxygen consumption and NYHA class at week 30: 37% with mavacamten vs 17% with placebo (difference 19.4%, 95% CI 8.7 to 30.1, p=0.0005), so the primary was met. Source: the peer-reviewed paper (Olivotto et al., Lancet 2020).

Next expected readout: December 2027 · NCT07004972 (registry estimate)

Reported efficacy

Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants (met)

Result source: NCT04349072

Results for Hypertrophic Cardiomyopathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

HRS-1893: no structured comparison results are available for Hypertrophic Cardiomyopathy.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mavacamten
Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants NCT04349072 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-1893's landscape · Mavacamten's landscape